Loading stock data…
Gain Therapeutics, Inc. (GANX)
$1.98+0.23 (+13.14%)
Market ClosedLast close Jun 29
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Gain Therapeutics, Inc. in the Healthcare sector is trading at $1.98 with a market capitalization of $76M. Wall Street consensus targets $7.20 (5 analysts), implying a +263.6% move over the next 12 months. The stock is currently near its 52-week low of $1.41, remaining 10.0% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +263.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.35M↓ | -$4.47M↑ | -$4.79M↑ | -$5.09M↓ | -$4.37M |
| Net Income | -$5.61M↓ | -$4.54M↑ | -$5.28M↑ | -$5.81M↓ | -$4.53M |
Peer Comparison
JNJUNHPFE
Fundamentals
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan di...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$76.35M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-151.64%
Volume
Today's trading volume
3.96M
Recent News
Why Is GANX Stock Rallying 22% After Hours?
The U.S. Food and Drug Administration (FDA) cleared Gain Therapeutics to begin a mid-stage clinical trial of its experimental drug GT-02287 in people with Parkinson’s disease.
Gain Therapeutics expands ‘compelling’ evidence base for Parkinson’s candidate
Gain Therapeutics’ Parkinson’s candidate GT-02287 showed durable clinical stability and biomarker improvements in extended Phase 1b data.
3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced
Most biotech stocks working towards a treatment for Parkinson's are already carrying a premium price. These three sit further off the radar, and analysts think the market has them badly wrong.
Gain Therapeutics (GANX) Shares Edge Higher After Narrower-Than-Expected Q1 Loss
Gain Therapeutics, Inc. (NASDAQ:GANX) shares rose 3.
3 US Biotechs Developing Parkinson’s Therapies
Global markets may be dealing with inflation, shifting rate expectations, and energy volatility, but companies tackling long-term health challenges like Parkinson’s disease are still pushing ahead.